| HOME >> BIOLOGY >> TECHNOLOGY |
3.4.2 Biomarker Discovery is Increasingly Happening Earlier in the Drug Discovery Process
3.4.3 Biomarkers Will Facilitate Patient Stratification - But What Does This Mean for the Blockbuster Model of Pharmaceutical Companies?
4. Overview of the World Biomarkers Market, 2011-2021
4.1 The World Biomarkers Market, 2011-2021
4.2 Oncology is a Rapidly Evolving Therapeutic Area for the Application of Biomarkers
4.3 Few Pharmaceutical Companies Have Dedicated Diagnostics Units: What Does This Mean for the Future of the Biomarkers Market?
4.4 The Current Model of Pharmaceutical R&D is Inefficient and Potentially a Restraint in Accelerating the Discovery of Novel Biomarkers and Drugs
5. Analysis of the World Biomarkers Market, 2011-2021
5.1 The World Biomarkers Market, 2010
5.2 The World Biomarkers Market, 2010-2015
5.3 The World Biomarkers Market, 2016-2021
5.4 Leading Therapeutic Areas within the World Biomarkers Market, 2010-2021
5.4.1 Overview
5.5 The Oncology Biomarkers Market, 2010-2021
5.5.1 The Oncology Biomarkers Market, 2010
5.5.2 The Oncology Biomarkers Market, 2010-2015
5.5.3 The Oncology Biomarkers Market, 2016-2021
5.6 Cardiovascular Biomarkers Market, 2010-2021
5.6.1 The Cardiovascular Biomarkers Market, 2010
5.6.2 The Cardiovascular Biomarkers Market, 2010-2015
5.6.3 The Cardiovascular Biomarkers Market, 2016-2021
5.7 Central Nervous System Biomarkers Market, 2010-2021
5.7.1 The Central Nervous System Biomarkers Market, 2010
5.7.2 The Central Nervous System Biomarkers Market, 2010-2015
5.7.3 The Central Nervous System Biomarkers Market, 2016-2021
5.8 Markets Driving Innovation in Biomarker Discovery, 2010-2021
5.8.1 Overview of Markets Driving Innovation in Biomarker Discovery, 2010
5.8.2 Proteomics and Biomarker Discovery, 2010-2021
5.8.2.1 Proteomics Mar
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |